Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 93 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Valvular Diseases Clear all

Conditions: Severe Aortic Stenosis
Interventions: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI), Surgical Aortic Valve Replacement (SAVR); Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: Not listed
Enrollment: 1,453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 45
States / cities: Phoenix, Arizona • Los Angeles, California • Mountain View, California + 35 more

Conditions: Cardiovascular Diseases
Interventions: Cardiovascular Magnetic Resonance; Diagnostic Test
Lead sponsor: Dipan Shah; Other
Eligibility: Not listed
Enrollment: 100,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2058
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pulmonary Vascular Disease, Valvular Heart Disease
Interventions: Echocardiogram; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Acute Coronary Syndrome
Interventions: Apolipoprotein A-I [human] (apoA-I), Placebo; Biological · Other
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 18,226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 202
States / cities: Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 175 more

Conditions: Atrial Fibrillation, Medication Adherence
Interventions: Medication Education; Other
Lead sponsor: Parkview Health; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Atrial Fibrillation
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Warfarin sodium; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 16,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Atrial Fibrillation, AFib
Interventions: AtriClip LAA Exclusion Device; Device
Lead sponsor: AtriCure, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: St. Helena, California • Miami, Florida • Indianapolis, Indiana + 4 more

Conditions: Ventricular Dysfunction, Pericardial Effusion, Valvular Disease, Septal Defect
Interventions: Philips EPIQ 7 ultrasound machine, Philips Lumify Broadband sector array transducer; Device
Lead sponsor: University of Miami; Other
Eligibility: Not listed
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Heart Failure, Cardiomyopathies, Pulmonary Hypertension, Myocarditis; Acute or Subacute, Myocarditis Due to Drug, Myocarditis Viral, Pericardial Diseases, Valvular Heart Diseases, Hypertension, Sepsis, Acute Kidney Injury, Pulmonary Edema - Acute, Pulmonary Edema With Heart Failure, Pulmonary Edemas, Acute Respiratory Distress Syndrome, Pulmonary Embolism Acute, Pulmonary Embolism (Diagnosis), Pulmonary Embolism Acute Massive, Pulmonary Embolism Subacute Massive, Venous Thrombosis Pulmonary, Venous Thrombosis (Disorder), Venous Thrombosis, Deep, Peripheral Arterial Disease, Peripheral Arterial Disease (PAD), Aortic Diseases, Muskuloskeletal Diseases, Brain Aging, Brain Aneurysm, Brain Aging Related Conditions, Ultrasound, Ultrasound Exams, Ultrasound Guidance
Interventions: OMNIPHYS Multimodal Ultrasound Imaging System; Device
Lead sponsor: Truway Health, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2046
U.S. locations: 1
States / cities: New York, New York

Conditions: Fibrillation, Atrial, Atrial Fibrillation
Interventions: SB424323; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 9
States / cities: Mobile, Alabama • Troy, Michigan • Akron, Ohio + 6 more

Conditions: Atrial Fibrillation
Interventions: Interrupted apixaban, Uninterrupted apixaban; Drug
Lead sponsor: Baim Institute for Clinical Research; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 19
States / cities: Huntsville, Alabama • Mission Viejo, California • New Haven, Connecticut + 16 more

Conditions: Valvular Heart Disease
Interventions: Not listed
Lead sponsor: Cardiovascular Research Foundation, New York; Other
Eligibility: 65 Years to 85 Years
Enrollment: 2,870 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Walnut Creek, California

Conditions: Atrial Fibrillation, Stroke
Interventions: warfarin, Dabigatran dose 1, Dabigatran dose 2; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 18,113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 374
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 286 more

Conditions: Cardiovascular Diseases, Heart Failure, Ischemic Heart Disease, Non-ischemic Cardiomyopathy, Valvular Heart Disease, Metabolic Cardiomyopathy, Congenital Heart Disease, Aortic Diseases, Atrial Fibrillation, Ventricular Fibrillation
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2037
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Congenital Disorders
Interventions: Not listed
Lead sponsor: Children's Healthcare of Atlanta; Other
Eligibility: Up to 21 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1976
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Valvular Heart Disease Patients, Aortic Stenosis, Mitral Regurgitation, Left Ventricular Diastolic Dysfunction
Interventions: Kosmos Torso-One AI-guided Point-of-Care Ultrasound (EchoNous, Inc.); Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 65 Years to 85 Years
Enrollment: 1,088 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Aortic Valve Stenosis, Mitral Regurgitation, Heart Murmurs, Valvular Heart Disease
Interventions: AS Algorithm 1, AS Algorithm 2, MR Algorithm 1, MR Algorithm 2; Diagnostic Test
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Atrial Fibrillation
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Warfarin; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 116,049 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Aortic Valve Disease, Aortic Valve Insufficiency, Aortic Regurgitation
Interventions: J-Valve TF System; Device
Lead sponsor: JC Medical, Inc., an affiliate of Edwards Lifesciences LLC; Industry
Eligibility: Not listed
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 9
States / cities: Scottsdale, Arizona • Washington D.C., District of Columbia • Oak Lawn, Illinois + 6 more

Conditions: Valvular Heart Disease, Aortic Valve Failure
Interventions: TELLTALE BASILICA procedure; Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years to 109 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: San Francisco, California • Fort Collins, Colorado • Washington D.C., District of Columbia + 7 more

Conditions: Non-valvular Atrial Fibrillation
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Atrial Fibrillation
Interventions: Apixaban, Warfarin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 60 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Valve Heart Disease, Aortic Stenosis, Aortic Regurgitation
Interventions: MRI with strain measurement, Echocardiography; Diagnostic Test
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Atrial Fibrillation, Atrial Flutter
Interventions: RSD1235; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: Fort Lauderdale, Florida • Atlanta, Georgia

Search by objective public record fields.

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement

DeBakey Cardiovascular Magnetic Resonance Study

A Study Of Clinical Implications Of Pulmonary Vascular Disease In Valvular Heart Disease

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

Use of Electronic Personal Health Records to Improve Medication Adherence

Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction

Stroke Feasibility Study

Focused Cardiac Ultrasound

Multimodal Physiologic State Intelligence Study

Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke

Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation

Age and Sex-Specific PREValence of AcqUirEd VALVular Heart DiseasE

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

Longitudinal Validation of CIRC Technologies

Children and Adolescents Receiving Mechanical and Prosthetic Valves

Importance of Point-of-Care Ultrasound for Early Detection of Valvular and Cardiac Diseases (IMPROVE)

Phono- and Electrocardiogram Assisted Detection of Valvular Disease

A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes

J-Valve TF Early Feasibility Study

NHLBI Transmural Electrosurgery LeafLet Traversal And Laceration Evaluation (TELLTALE) BASILICA-TAVR Trial

Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized With PCI - The AVIATOR 2 Registry

Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation

Comparative Imaging Assessment of Valvular Heart Disease

Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery